Wake Forest University Health Sciences: Lymphoma, Non-Hodgkin trials
The registry lists 12 Lymphoma, Non-Hodgkin studies with Wake Forest University Health Sciences as lead sponsor. 3 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 2No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsRecruitingNCT06418204
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
- CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin LymphomaTerminatedNCT04217317Phase 2Results posted
- Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among SurvivorsCompletedNCT03935282Not applicableResults posted
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
- Improving Exercise Capacity With a Tailored Physical Activity InterventionActive, not recruitingNCT05595577Not applicable
- B-Cell Hematologic Malignancy Vaccination RegistryWithdrawnNCT02298816
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable